Profile data is unavailable for this security.
About the company
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. Its chromatography franchise includes several products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. Its TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. Its desktop portfolio includes MAVERICK and MAVEN, REBEL, and ZipChip.
- Revenue in USD (TTM)707.89m
- Net income in USD1.74m
- Incorporated1981
- Employees1.78k
- LocationRepligen CorpBUILDING 1, SUITE 100, 41 SEYON STREETWALTHAM 02453United StatesUSA
- Phone+1 (781) 449-9560
- Fax+1 (302) 655-5049
- Websitehttps://www.repligen.com/
More ▼
Mergers & acquisitions
| Acquired company | RGEN:NSQ since announced | Transaction value |
|---|---|---|
| 908 Devices GmbH | -12.19% | 70.00m |
Data delayed at least 15 minutes, as of Feb 13 2026 21:00 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teleflex Inc | 3.19bn | -327.85m | 4.59bn | 14.10k | -- | 1.20 | -- | 1.44 | -7.35 | -7.36 | 70.55 | 86.48 | 0.4154 | 2.05 | 6.00 | 226,240.30 | -4.27 | 4.58 | -4.69 | 5.01 | 53.67 | 54.77 | -10.28 | 11.38 | 1.53 | 6.78 | 0.4114 | 19.74 | 2.45 | 3.26 | -80.38 | -31.40 | 4.25 | 0.00 |
| Lantheus Holdings Inc | 1.53bn | 167.68m | 4.60bn | 808.00 | 29.14 | 4.11 | 19.81 | 3.02 | 2.38 | 2.38 | 21.90 | 16.88 | 0.7055 | 8.67 | 4.48 | 1,888,531.00 | 7.75 | 9.87 | 10.50 | 11.33 | 62.23 | 60.44 | 10.99 | 12.86 | 2.49 | -- | 0.337 | 0.00 | 18.32 | 34.59 | -4.35 | 58.06 | 29.27 | -- |
| iRhythm Holdings, Inc | 702.57m | -51.46m | 4.65bn | 2.00k | -- | 38.10 | -- | 6.61 | -1.62 | -1.62 | 22.11 | 3.78 | 0.7377 | 12.04 | 9.15 | 351,286.50 | -5.40 | -20.12 | -6.21 | -24.37 | 70.35 | 68.61 | -7.32 | -23.90 | 4.50 | -- | 0.8418 | -- | 20.13 | 22.50 | 8.20 | -- | 19.06 | -- |
| Envista Holdings Corp | 2.72bn | 47.00m | 4.75bn | 12.00k | 105.36 | 1.53 | 29.13 | 1.75 | 0.275 | 0.275 | 16.10 | 18.96 | 0.4931 | 4.62 | 6.86 | 226,625.00 | 0.8523 | -2.14 | 1.01 | -2.58 | 55.02 | 56.70 | 1.73 | -5.21 | 2.04 | 6.70 | 0.318 | -- | 8.32 | 7.11 | 104.20 | 2.03 | -1.03 | -- |
| Merit Medical Systems Inc | 1.48bn | 118.43m | 4.84bn | 7.40k | 41.80 | 3.17 | 19.79 | 3.28 | 1.95 | 1.95 | 24.37 | 25.80 | 0.5898 | 2.39 | 7.38 | 199,611.90 | 4.73 | 3.49 | 5.17 | 3.93 | 48.47 | 45.37 | 8.02 | 5.65 | 2.86 | 14.41 | 0.324 | 0.00 | 7.89 | 6.40 | 27.48 | 85.69 | -14.13 | -- |
| Stevanato Group SpA | 1.39bn | 166.85m | 4.85bn | 5.52k | 26.19 | 2.56 | 18.22 | 3.49 | 0.6113 | 0.6113 | 5.09 | 6.25 | 0.5058 | 2.95 | 2.65 | 251,569.00 | 6.08 | 8.02 | 7.63 | 10.94 | 29.27 | 31.01 | 12.01 | 13.24 | 1.30 | 30.00 | 0.2386 | 6.82 | 1.72 | 15.53 | -19.13 | 24.61 | 33.52 | -- |
| Bruker Corp | 3.44bn | -22.50m | 5.55bn | 11.40k | -- | 2.24 | 27.86 | 1.61 | -0.1487 | -0.1487 | 22.61 | 16.28 | 0.5705 | 1.67 | 5.71 | -- | -0.1212 | 5.07 | -0.155 | 6.76 | 46.70 | 49.41 | -0.2124 | 7.56 | 0.8739 | 7.79 | 0.4268 | 13.13 | 2.08 | 11.57 | -119.89 | -- | 4.34 | 4.56 |
| Caris Life Sciences Inc | -100.00bn | -100.00bn | 5.82bn | -- | -- | 12.16 | -- | -- | -- | -- | -- | 1.70 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 9.36 | -- | 0.4404 | -- | 34.67 | -- | 18.22 | -- | -- | -- |
| Avantor Inc | 6.55bn | -530.20m | 6.27bn | 13.50k | -- | 1.13 | -- | 0.9577 | -0.7775 | -0.7775 | 9.62 | 8.16 | 0.5481 | 5.70 | 6.21 | 485,348.20 | -4.44 | 2.78 | -5.17 | 3.18 | 32.65 | 33.77 | -8.09 | 5.00 | 1.18 | 3.61 | 0.4149 | 0.00 | -3.41 | 0.4913 | -174.52 | -- | 15.90 | -- |
| Glaukos Corp | 469.82m | -87.61m | 6.29bn | 995.00 | -- | 8.16 | -- | 13.38 | -1.55 | -1.55 | 8.28 | 13.41 | 0.4879 | 1.76 | 6.06 | 472,180.90 | -9.10 | -11.24 | -9.92 | -12.04 | 76.87 | 73.54 | -18.65 | -36.68 | 4.47 | -- | 0.0817 | -- | 21.85 | 10.10 | -8.70 | -- | 5.93 | -- |
| Bio Rad Laboratories Inc | 2.56bn | -675.90m | 6.92bn | 7.70k | -- | 1.03 | -- | 2.71 | -24.30 | -24.30 | 92.91 | 249.77 | 0.252 | 1.53 | 5.52 | 332,139.60 | -6.66 | 3.00 | -7.01 | 3.15 | 52.42 | 55.37 | -26.43 | 14.51 | 3.94 | 0.2476 | 0.1515 | 0.00 | -3.92 | 2.11 | -189.37 | -- | 13.91 | -- |
| Masimo Corp | 1.72bn | -203.80m | 6.99bn | 3.60k | -- | 8.53 | -- | 4.08 | -3.83 | -10.61 | 31.70 | 15.25 | 0.6993 | 1.70 | 5.09 | 476,416.70 | -8.31 | 3.29 | -10.46 | 3.99 | 54.96 | 53.94 | -11.88 | 4.56 | 1.92 | 5.88 | 0.4084 | 0.00 | 2.26 | 17.43 | -474.11 | -- | -6.75 | -- |
| Repligen Corp | 707.89m | 1.74m | 7.68bn | 1.78k | 5,298.64 | 3.69 | 92.49 | 10.85 | 0.0258 | 0.0258 | 12.55 | 37.01 | 0.246 | 2.00 | 5.09 | 398,138.30 | 0.0604 | 3.28 | 0.063 | 3.70 | 51.59 | 54.24 | 0.2455 | 12.37 | 7.14 | -- | 0.2052 | 0.00 | 0.3285 | 18.61 | -171.68 | -- | 5.25 | -- |
| Henry Schein Inc | 12.94bn | 391.00m | 9.20bn | 25.00k | 24.70 | 2.76 | 13.04 | 0.7115 | 3.17 | 3.17 | 104.73 | 28.35 | 1.19 | 4.86 | 7.60 | 517,520.00 | 3.70 | 5.43 | 6.36 | 9.19 | 31.19 | 30.23 | 3.10 | 3.98 | 0.7885 | 6.59 | 0.3872 | 0.00 | 2.71 | 4.88 | -6.25 | -11.06 | 19.66 | -- |
| Baxter International Inc | 11.02bn | -355.00m | 10.18bn | 38.00k | -- | 1.40 | 16.08 | 0.9237 | -0.6925 | -0.6654 | 21.46 | 14.09 | 0.4618 | 3.14 | 6.08 | 290,078.90 | -1.48 | -0.8441 | -1.87 | -1.03 | 35.05 | 38.63 | -3.20 | -2.03 | 1.18 | 3.42 | 0.5684 | -- | 2.66 | -1.31 | -293.68 | -- | -8.52 | 1.60 |
Data as of Feb 13 2026. Currency figures normalised to Repligen Corp's reporting currency: US Dollar USD
44.83%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Dec 2025 | 4.69m | 8.33% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 4.59m | 8.16% |
| T. Rowe Price Associates, Inc. (IM)as of 30 Sep 2025 | 3.46m | 6.14% |
| United Capital Financial Advisors LLCas of 30 Sep 2025 | 2.76m | 4.90% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2025 | 2.29m | 4.07% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 1.72m | 3.05% |
| Citadel Advisors LLCas of 30 Sep 2025 | 1.68m | 2.99% |
| Point72 Asset Management LPas of 30 Sep 2025 | 1.55m | 2.76% |
| Holocene Advisors, LPas of 30 Sep 2025 | 1.38m | 2.45% |
| Massachusetts Financial Services Co.as of 31 Dec 2025 | 1.12m | 1.99% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
